Patents by Inventor H. Perry Fell

H. Perry Fell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Patent number: 7915395
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: March 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell, Lisa K. Gilliland
  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Publication number: 20030219876
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein.
    Type: Application
    Filed: October 29, 2002
    Publication date: November 27, 2003
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell, Lisa K. Gilliland
  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Patent number: 6482919
    Abstract: The present invention provides novel soluble CTLA4Ig molecules having modified Ig domains.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: November 19, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell, Lisa K. Gilliland
  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Publication number: 20020012989
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein.
    Type: Application
    Filed: March 21, 2001
    Publication date: January 31, 2002
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell, Lisa K. Gilliland
  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Patent number: 6132992
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.
    Type: Grant
    Filed: October 5, 1995
    Date of Patent: October 17, 2000
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Jeffrey A. Ledbetter, Lisa K. Gilliland, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell
  • Mixed specificity fusion proteins
    Patent number: 5709859
    Abstract: Mixed specificity fusion proteins capable of binding to cellular adhesion molecules have been produced. The fusion proteins contain a polypeptide region, such as an IgG constant region, operatively attached to at least two binding regions each of which corresponds to either an extracellular domain of a cell surface receptor for cellular adhesion molecules, or a variable region of an antibody directed to a cellular adhesion molecule.A method of inhibiting inflammation is a patient is disclosed in which the present fusion proteins are administered to a patient to inhibit the attachment of inflammatory cells to vascular endothelium.A method of inhibiting metastasis is disclosed in which the present fusion proteins are administered to a patient to inhibit the metastasis of responsive tumor cells.
    Type: Grant
    Filed: January 24, 1991
    Date of Patent: January 20, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alejandro A. Aruffo, Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, H. Perry Fell, Jr.
  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Patent number: 5637481
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen.
    Type: Grant
    Filed: September 13, 1993
    Date of Patent: June 10, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Ledbetter, Lisa K. Gilliland, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell
  • Production of chimeric antibodies by homologous recombination
    Patent number: 5482856
    Abstract: A process for producing chimeric antibodies using novel recombinant DNA vectors and homologous recombination in vivo is described. The recombinant DNA constructs of the invention can be used to transfect antibody producing cells so that targeted homologous recombination occurs in the transfected cells leading to gene modification and the production of chimeric antibody molecules by the transfected cells.
    Type: Grant
    Filed: April 12, 1993
    Date of Patent: January 9, 1996
    Assignee: Oncogen Inc.
    Inventors: H. Perry Fell, Jr., Kim R. Folger-Bruce, Susan M. Yarnold
  • Production of chimeric antibodies by homologous recombination
    Patent number: 5204244
    Abstract: A process for producing chimeric antibodies using novel recombinant DNA vectors and homologous recombination in vivo is described. The recombinant DNA constructs of the invention can be used to transfect antibody producing cells so that targeted homologous recombination occurs in the transfected cells leading to gene modification and the production of chimeric antibody molecules by the transfected cells.
    Type: Grant
    Filed: September 14, 1988
    Date of Patent: April 20, 1993
    Assignee: Oncogen
    Inventors: H. Perry Fell, Kim R. Folger Bruce
  • Production of chimeric antibodies by homologous recombination
    Patent number: 5202238
    Abstract: A process for producing chimeric antibodies using novel recombinant DNA vectors and homologous recombination in vivo is described. The recombinant DNA constructs of the invention can be used to transfect antibody producing cells so that targeted homologous recombination occurs in the transfected cells leading to gene modification and the production of chimeric antibody molecules by the transfected cells.
    Type: Grant
    Filed: January 22, 1990
    Date of Patent: April 13, 1993
    Assignee: Oncogen
    Inventors: H. Perry Fell, Jr., Kim R. Folger-Bruce